LP 105
Alternative Names: LP-105Latest Information Update: 18 Oct 2021
At a glance
- Originator Linton Pharm
- Class Anti-infectives; Bispecific antibodies
- Mechanism of Action CD3 antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Infections
Most Recent Events
- 18 Oct 2021 Preclinical trials in Infections in China (Parenteral), before October 2021 (Linton Pharm pipeline, October 2021)
- 12 Jun 2020 LP 105 is available for licensing as of 12 Jun 2020. http://www.lintonpharm.com/
- 12 Jun 2020 Early research in Infections in China (Parenteral) (Linton Pharm pipeline, June 2020)